Category survey

Disease progression in Parkinson’s disease (PD) – a-Synuclein and Sirtuin 2 as biomarker and biological aspects of their interaction Investments < €500k Norway 2016    

Parkinson’s disease progression: Prediction, impact and biomarkers. Investments < €500k Norway 2016    

Biology of sleep disorders in patients with Parkinson’s disease Investments < €500k Norway 2016    

Early detection of cognitive decline and dementia in Parkinson’s disease Investments < €500k Norway 2016    

Uncovering genetic predisposition to early onset dementia in patients with Parkinson’s disease Investments < €500k Norway 2016    

Impulse Control Disorders in Parkinson’s Disease Investments < €500k Norway 2016    

A common mitochondrial pathogenesis for Parkinson’s disease: elucidating disease mechanisms and designing treatments Investments < €500k Norway 2016    

Integrated functional and structural neuroimaging in movement disorders Investments < €500k Norway 2016    

Genetiske forhold ved demens med lewylegemer -Genetic conditions in dementia with lewy bodies Investments < €500k Norway 2016    

The Norwegian ParkWest study Investments < €500k Norway 2016    

Novel risk factor assay for Alzheimer’s disease-Multi-parametric quantification of HPG/HPT- axis dysfunction Investments < €500k Norway 2016    

Development of novel strategies for treating Alzheimer’s disease by understanding glial mechanisms for brain waste removal Investments < €500k Norway 2016    

Validation of mild cognitive impairment in Parkinson’s disease Investments < €500k Netherlands 2016    

Clinical follow-up on the development of impulse control disorders in Parkinson’s disease Investments < €500k Netherlands 2016    

NSTAPS studie – tweede termijn van driejaars en vijfjaars follow-up. NSTAPS study – second term of three-year and five-year follow-up Investments < €500k Netherlands 2016    

Mondgezondheid van mensen met de ziekte van Parkinson in Nederland. Oral health of people with Parkinson’s disease in the Netherlands Investments < €500k Netherlands 2016    

Improving cognitive functioning in Parkinson’s Disease with transcranial Direct Current Stimulation. Investments < €500k Netherlands 2016    

Inhaleerbare levodopa voor gebruik tijdens een off periode bij patiënten met de ziekte van Parkinson. Inhalable levodopa for use during an off period in patients with Parkinson’s disease Investments < €500k Netherlands 2016    

Online cognitieve training bij de ziekte van Parkinson. Online cognitive training in Parkinson’s disease Investments < €500k Netherlands 2016    

CHEVAL-in: neurophysiological determinants of conversion to psychosis and response to cholinesterase inhibitors in Parkinson’s disease Investments < €500k Netherlands 2016    

Voorspellende factoren voor het beloop van de ziekte van Parkinson over zeer lange termijn. Forecasting factors for the course of Parkinson’s disease in a very long term Investments < €500k Netherlands 2016    

ALS behandelrichtlijn Investments < €500k Netherlands 2016    

Project ALS Treatment Institute (TRICALS) Investments < €500k Netherlands 2016    

Project Itwin Investments < €500k Netherlands 2016    

Project Neuro Imaging Society in ALS (Nisals) Investments < €500k Netherlands 2016    

De rol van een verhoogde stofwisseling bij ALS Investments < €500k Netherlands 2016    

Parelsnoer en Biomarkers Investments < €500k Netherlands 2016    

Alzheimer pathology: swimming against the current Investments < €500k Netherlands 2016    

Longitudinal DLB Cohort Investments < €500k Netherlands 2016    

Amyloid in the retina Investments < €500k Netherlands 2016    

Identifying therapeutic targets and causes of dopaminergic neuronal degeneration using C. elegans high-throughput genetic approaches Investments < €500k Norway 2016    

Dementia Disease Initiation Investments < €500k Norway 2016    

Effecten van Aß op synapses die inhibitie aansturen. Effects of Aβ on synapses that control inhibition Investments < €500k Netherlands 2016    

Regulatie van lysosomale enzym-activiteit bij de ziekte van Alzheimer. Regulation of lysosomal enzyme activity in Alzheimer’s disease Investments < €500k Netherlands 2016    

NILVAD CBF ADD-on study: The effects of nilvadipine on Cerebral autoregulation, Blood pressure, cerebral blood Flow and -Damage in Alzheimer’s Disease. Investments < €500k Netherlands 2016    

Whole exome sequencing in familial Alzheimer’s disease without APP/PSEN gene mutations Investments < €500k Netherlands 2016    

Functional brain connectivity: a new imaging marker for preclinical Investments < €500k Netherlands 2016    

Blood-brain barrier leakage in dementia Investments < €500k Netherlands 2016    

Whole Genome Sequencing; 100plus Study Investments < €500k Netherlands 2016    

The Dutch Flutemetamol in Young Onset Dementia Study Investments < €500k Netherlands 2016    

Symptomatic Treatment of Vascular Cognitive Impairment Investments < €500k Netherlands 2016    

Empowering people with dementia: green care farms as an alternative to traditional dementia care environments. Investments < €500k Netherlands 2016    

Through the D’mentia Lens: an easy accessible dementia simulation for family caregivers using the innovative Oculus Rift VR headset, combined with e-learning; Investments < €500k Netherlands 2016    

Deep brain stimulation surgery under local versus general anesthesia in Parkinson’s disease Investments < €500k Netherlands 2016    

Developing a SCA1 therapy targeting the ataxin-1 protein in a patient-specific neuronal cell model Investments < €500k Netherlands 2016    

De ontwikkeling van een ALS therapie gericht op Ataxine-2. The development of an ALS therapy focused on Ataxin-2 Investments < €500k Netherlands 2016    

Antisense oligonucleotide mediated exon skipping to remove the expanded polyQ repeat from the ataxin 3 protein in Spinocerebellar Ataxia 3 Investments < €500k Netherlands 2016    

Focus on the locus network with 7Tesla MRI: from normal to impaired memory Investments < €500k Netherlands 2016    

Functional markers for cognitive disorders Investments < €500k Netherlands 2016    

Slaap- en stemmingsstoornissen bij de ziekte van Parkinson; een behandelstudie met lichttherapie. Sleep and mood disorders in Parkinson’s disease; A treatment study with light therapy Investments < €500k Netherlands 2016